These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3508329)

  • 1. Steady state pharmacokinetics of naproxen in young and elderly healthy volunteers.
    Cohen A; Basch C
    Semin Arthritis Rheum; 1988 Feb; 17(3 Suppl 2):7-11. PubMed ID: 3508329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine.
    Haberer LJ; Walls CM; Lener SE; Taylor DR; McDonald SA
    Headache; 2010 Mar; 50(3):357-73. PubMed ID: 20132340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers.
    Gøtzsche PC; Andreasen F; Egsmose C; Lund B
    Scand J Rheumatol; 1988; 17(1):11-6. PubMed ID: 3259332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of high-dosage naproxen in elderly patients.
    Van den Ouweland FA; Jansen PA; Tan Y; Van de Putte LB; Van Ginneken CA; Gribnau FW
    Int J Clin Pharmacol Ther Toxicol; 1988 Mar; 26(3):143-7. PubMed ID: 3410597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of naproxen at two dosage regimens in healthy volunteers.
    Franssen MJ; Tan Y; van de Putte LB; van Ginneken CA; Gribnau FW
    Int J Clin Pharmacol Ther Toxicol; 1986 Mar; 24(3):139-42. PubMed ID: 3699940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple-dose pharmacokinetics of naproxen from a controlled-release tablet in healthy volunteers.
    Palazzini E; Galli G; Babbini M
    Int J Clin Pharmacol Res; 1990; 10(5):277-84. PubMed ID: 2079385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state pharmacokinetics of enteric-coated naproxen tablets compared with standard naproxen tablets.
    Jung D; Schwartz KE
    Clin Ther; 1994; 16(6):923-9. PubMed ID: 7697688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
    Berges A; Walls C; Lener SE; McDonald SA
    Clin Ther; 2010 Jun; 32(6):1165-77. PubMed ID: 20637969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans.
    Caillé G; du Souich P; Besner JG; Gervais P; Vézina M
    Am J Med; 1989 Jun; 86(6A):38-44. PubMed ID: 2735334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
    Choi Y; Han H; Shin D; Lim KS; Yu KS
    Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacokinetic comparison of controlled-release and standard naproxen tablets.
    Ryley NJ; Lingam G
    Curr Med Res Opin; 1988; 11(1):10-5. PubMed ID: 3383611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multiple-dose pharmacokinetic comparison of naproxen as a once-daily controlled-release tablet and a twice-daily conventional tablet.
    Ling TL; Yee JP; Cohen A; Hsiao C; Gonzalez MA; Garg DC; Weidler DJ
    J Clin Pharmacol; 1987 Apr; 27(4):325-9. PubMed ID: 3680592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability, food effect and tolerability of S-naproxen betainate sodium salt monohydrate in steady state.
    Marzo A; Dal Bo L; Wool C; Cerutti R
    Arzneimittelforschung; 1998 Sep; 48(9):935-40. PubMed ID: 9793622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations.
    Day RO; Francis H; Vial J; Geisslinger G; Williams KM
    J Rheumatol; 1995 Dec; 22(12):2295-303. PubMed ID: 8835565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single- and multiple-dose pharmacokinetic comparison of a sustained-release tablet and conventional tablets of naproxen in healthy volunteers.
    Zhou D; Zhang Q; Lu W; Xia Q; Wei S
    J Clin Pharmacol; 1998 Jul; 38(7):625-9. PubMed ID: 9702847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naproxen pharmacokinetics in the elderly.
    Upton RA; Williams RL; Kelly J; Jones RM
    Br J Clin Pharmacol; 1984 Aug; 18(2):207-14. PubMed ID: 6487459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of concurrent sucralfate administration on pharmacokinetics of naproxen.
    Caille G; du Souich P; Gervais P; Besner JG; Vezina M
    Am J Med; 1987 Sep; 83(3B):67-73. PubMed ID: 3661612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney function during naproxen therapy in patients at risk for renal insufficiency.
    Watson WA; Freer JP; Katz RS; Basch C
    Semin Arthritis Rheum; 1988 Feb; 17(3 Suppl 2):12-6. PubMed ID: 3508327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.